Michiie Sakamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michiie Sakamoto has a total of 423 co-authors. Here are the top co-authors by number of shared publications:
- Yohei Masugi
Department of Pathology, School of Medicine Tokai University Isehara Japan
96 shared publications - Yuko Kitagawa
Department of Surgery, Keio University School of Medicine , Tokyo
60 shared publications - Makoto Suematsu
Keio University
54 shared publications - Yasuaki Kabe
Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan
54 shared publications - Aiko Nagayama
Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, USA
53 shared publications - Akiko Kubo
Division of Dermatology, Department of Internal Related Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
53 shared publications
Latest Publications
- 1 April 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (2) , 203-205
Macrotrabecular hepatocellular carcinoma: Unique immunovascular characteristics
An abstract is unavailable. This article is available as a PDF only.
- 1 April 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (2) , 203-205
Macrotrabecular hepatocellular carcinoma: Unique immunovascular characteristics
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 7 January 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (4) , 362-371
Chronological changes in etiology, pathological and imaging findings in primary liver cancer from 2001 to 2020
Purpose: To achieve a historical perspective, the chronological changes in primary liver cancer over a 20-year period were investigated at a single institution, focusing on shifts in etiology and the impact on imaging and pathological findings using The Liver Imaging Reporting and Data System. Materials and methods: A retrospective study of surgically resected primary liver cancer in 680 patients from 2001 to 2020 resulted in 434 patients with 482 nodules being analyzed. Dynamic contrast-enhanced computed tomography imaging and the Liver Imaging Reporting and Data System 2018 classification were employed. Two pathologists and two radiologists independently evaluated specimens and images. Results: This study highlighted a significant decline in cases of viral hepatitis and cirrhosis in primary liver cancer patients but an increase in intrahepatic cholangiocarcinoma and scirrhous hepatocellular carcinoma. Notably, there was a rise in non-viral hepatitis cases, potentially pointing toward an increase in steatohepatitic hepatocellular carcinoma cases in the future. Intrahepatic cholangiocarcinoma, scirrhous hepatocellular carcinoma and steatohepatitic hepatocellular carcinoma tumors exhibited slightly different distributions in the Liver Imaging Reporting and Data System classification compared with ordinary hepatocellular carcinoma, which may reflect the presence of fibrosis and lipid in tumor parenchyma. Conclusions: Consistent with past reports, this study demonstrated the emergence of primary liver cancer against a backdrop of non-viral and non-cirrhotic liver. Liver Imaging Reporting and Data System has been consistently useful in diagnosing primary liver cancer; however, among the histological subtypes of hepatocellular carcinoma, an increase is anticipated in scirrhous hepatocellular carcinoma and steatohepatitic hepatocellular carcinoma, which may present imaging findings different from those of ordinary hepatocellular carcinoma. This development may necessitate a reevaluation of the current approach for diagnosing and treating hepatocellular carcinoma based solely on imaging.
- 7 January 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (4) , 362-371
Open AccessChronological changes in etiology, pathological and imaging findings in primary liver cancer from 2001 to 2020
Purpose: To achieve a historical perspective, the chronological changes in primary liver cancer over a 20-year period were investigated at a single institution, focusing on shifts in etiology and the impact on imaging and pathological findings using The Liver Imaging Reporting and Data System. Materials and methods: A retrospective study of surgically resected primary liver cancer in 680 patients from 2001 to 2020 resulted in 434 patients with 482 nodules being analyzed. Dynamic contrast-enhanced computed tomography imaging and the Liver Imaging Reporting and Data System 2018 classification were employed. Two pathologists and two radiologists independently evaluated specimens and images. Results: This study highlighted a significant decline in cases of viral hepatitis and cirrhosis in primary liver cancer patients but an increase in intrahepatic cholangiocarcinoma and scirrhous hepatocellular carcinoma. Notably, there was a rise in non-viral hepatitis cases, potentially pointing toward an increase in steatohepatitic hepatocellular carcinoma cases in the future. Intrahepatic cholangiocarcinoma, scirrhous hepatocellular carcinoma and steatohepatitic hepatocellular carcinoma tumors exhibited slightly different distributions in the Liver Imaging Reporting and Data System classification compared with ordinary hepatocellular carcinoma, which may reflect the presence of fibrosis and lipid in tumor parenchyma. Conclusions: Consistent with past reports, this study demonstrated the emergence of primary liver cancer against a backdrop of non-viral and non-cirrhotic liver. Liver Imaging Reporting and Data System has been consistently useful in diagnosing primary liver cancer; however, among the histological subtypes of hepatocellular carcinoma, an increase is anticipated in scirrhous hepatocellular carcinoma and steatohepatitic hepatocellular carcinoma, which may present imaging findings different from those of ordinary hepatocellular carcinoma. This development may necessitate a reevaluation of the current approach for diagnosing and treating hepatocellular carcinoma based solely on imaging.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Purpose:Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their differentiation. Nevertheless, the spatial distribution of these immune cells with distinct phenotypes in the tumor microenvironment and their clinicopathologic significance in resectable and unresectable HCCs are still largely unclear.Experimental Design:We analyzed the spatial dynamics of intratumoral CD4 and CD8 T cells and their association with B and plasma cells using 283 surgically resected HCC samples, 58 unresectable HCC samples before combined immunotherapy [atezolizumab plus bevacizumab (Atezo + Bev)], and autopsy specimens from 50 cases of advanced-stage HCC through multiplex IHC combined with transcriptomic and driver gene mutation analyses. Classification based on the spatial dynamics of T- and B-cell responses (refined immunosubtype) was developed, and its clinicopathologic significance was analyzed.Results:We found that stem-like CD4 and CD8 T cells were mainly observed in T-cell aggregates and T-cell zone of tertiary lymphoid structure (TLS). The differentiation of T follicular helper cells was associated with the development of TLS, whereas the differentiation of CXCL13-expressing CD4 TCXCL13 cells with a phenotype resembling T peripheral helper cells was associated with the development of the lymphoplasmacytic microenvironment. The refined immunosubtype could predict clinical outcomes of resectable HCC after surgery and unresectable HCC after Atezo + Bev therapy. The immune microenvironment of metastatic lesions tended to reflect those of primary lesions.Conclusions:We revealed the spatial dynamics of T- and B-cell responses in HCC, which is closely associated with the clinical outcome after surgical resection or Atezo + Bev therapy.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Purpose:Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their differentiation. Nevertheless, the spatial distribution of these immune cells with distinct phenotypes in the tumor microenvironment and their clinicopathologic significance in resectable and unresectable HCCs are still largely unclear.Experimental Design:We analyzed the spatial dynamics of intratumoral CD4 and CD8 T cells and their association with B and plasma cells using 283 surgically resected HCC samples, 58 unresectable HCC samples before combined immunotherapy [atezolizumab plus bevacizumab (Atezo + Bev)], and autopsy specimens from 50 cases of advanced-stage HCC through multiplex IHC combined with transcriptomic and driver gene mutation analyses. Classification based on the spatial dynamics of T- and B-cell responses (refined immunosubtype) was developed, and its clinicopathologic significance was analyzed.Results:We found that stem-like CD4 and CD8 T cells were mainly observed in T-cell aggregates and T-cell zone of tertiary lymphoid structure (TLS). The differentiation of T follicular helper cells was associated with the development of TLS, whereas the differentiation of CXCL13-expressing CD4 TCXCL13 cells with a phenotype resembling T peripheral helper cells was associated with the development of the lymphoplasmacytic microenvironment. The refined immunosubtype could predict clinical outcomes of resectable HCC after surgery and unresectable HCC after Atezo + Bev therapy. The immune microenvironment of metastatic lesions tended to reflect those of primary lesions.Conclusions:We revealed the spatial dynamics of T- and B-cell responses in HCC, which is closely associated with the clinical outcome after surgical resection or Atezo + Bev therapy.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S4. Clinicopathological findings in cases treated with Atezo+Bev therapy
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S4. Clinicopathological findings in cases treated with Atezo+Bev therapy
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S2. Example of histocytometric analysis
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S2. Example of histocytometric analysis
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S5. Intratumoral distribution of NK cells
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S5. Intratumoral distribution of NK cells
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S3. Multivariate analysis for DFS in Cohort 1 + 2 (n = 268)
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S3. Multivariate analysis for DFS in Cohort 1 + 2 (n = 268)
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S7. CD68+ and CD169+ macrophages in TA/TLS
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S7. CD68+ and CD169+ macrophages in TA/TLS
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S6. Clinicopathological findings in autopsy cases.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S6. Clinicopathological findings in autopsy cases.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S4. TCF1 expression in TA and TLS
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S4. TCF1 expression in TA and TLS